Rising US Sales, EU Milestone Boost SK Bio's Q1
Shift To Operating Profit
Executive Summary
After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.
You may also be interested in...
Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others
Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.